Shuang Tong

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Wenwen Zhang, Shuang Tong, Bingyang Hu et al. · Journal for ImmunoTherapy of Cancer · 2023 · 126 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer

Yuezong Bai, Tong Xie, Zhenghang Wang et al. · Journal for ImmunoTherapy of Cancer · 2022 · 104 citations · Full text

Medicine, Immunology, Oncology +17

Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway

Jing Wen, Yi Yang, Guangyu Zhao et al. · Vaccine · 2012 · 43 citations

Life Sciences, Immunology, Microbiology +14

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study

Xiaofeng Chen, Hao Xu, Xiaobing Chen et al. · Signal Transduction and Targeted Therapy · 2024 · 43 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Tissue-specific expression of the NOD-like receptor protein 3 in BALB/c mice

Zhiqiang Huang, Meng Yu, Shuang Tong et al. · Journal of Veterinary Science · 2014 · 23 citations · Full text

Life Sciences, Immunology, Pathology +15